These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35664258)

  • 1. Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies.
    Li D; Partin AC; Zhao L; Chen I; Michaels ML; Wang Z; Garces F; Gong D; Riley TP
    STAR Protoc; 2022 Jun; 3(2):101428. PubMed ID: 35664258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intein mediated high throughput screening for bispecific antibodies.
    Hofmann T; Schmidt J; Ciesielski E; Becker S; Rysiok T; Schütte M; Toleikis L; Kolmar H; Doerner A
    MAbs; 2020; 12(1):1731938. PubMed ID: 32151188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.
    Dhimolea E; Reichert JM
    MAbs; 2012; 4(1):4-13. PubMed ID: 22327426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models.
    Wang F; Tsai JC; Davis JH; Chau B; Dong J; West SM; Hogan JM; Wheeler ML; Bee C; Morishige W; Cayton T; David-Brown D; Zhang C; Kozhich A; Sproul T; Dollinger G; Rajpal A; Strop P
    MAbs; 2020; 12(1):1685350. PubMed ID: 31856660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape.
    Suryadevara N; Gilchuk P; Zost SJ; Mittal N; Zhao LL; Crowe JE; Carnahan RH
    STAR Protoc; 2022 Jun; 3(2):101387. PubMed ID: 35578733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibody process development: Assembly and purification of knob and hole bispecific antibodies.
    Giese G; Williams A; Rodriguez M; Persson J
    Biotechnol Prog; 2018 Mar; 34(2):397-404. PubMed ID: 29193902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies: molecules that enable novel therapeutic strategies.
    Fischer N; Léger O
    Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments.
    McGuinness BT; Walter G; FitzGerald K; Schuler P; Mahoney W; Duncan AR; Hoogenboom HR
    Nat Biotechnol; 1996 Sep; 14(9):1149-54. PubMed ID: 9631069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production and purification of recombinant monoclonal antibodies from human cells based on a primary sequence.
    DeLuca KF; Mick JE; DeLuca JG
    STAR Protoc; 2022 Dec; 3(4):101915. PubMed ID: 36595892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for predicting drug-resistant protein mutations to an ERK2 inhibitor using RESISTOR.
    Guerin N; Kaserer T; Donald BR
    STAR Protoc; 2023 Apr; 4(2):102170. PubMed ID: 37115667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
    Yang F; Wen W; Qin W
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid-phase bioconjugation of heterobifunctional adaptors for versatile assembly of bispecific targeting ligands.
    Liu HY; Zrazhevskiy P; Gao X
    Bioconjug Chem; 2014 Aug; 25(8):1511-6. PubMed ID: 25010411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 proteome microarray for COVID-19 patient sera profiling.
    Lai DY; Jiang HW; Li Y; Zhang HN; Tao SC
    STAR Protoc; 2022 Jun; 3(2):101238. PubMed ID: 35310073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Greatest Hits-Innovative Technologies for High Throughput Identification of Bispecific Antibodies.
    Hofmann T; Krah S; Sellmann C; Zielonka S; Doerner A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fine-tuning bispecific therapeutics.
    Lim SI
    Pharmacol Ther; 2020 Aug; 212():107582. PubMed ID: 32450189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies.
    Patke S; Li J; Wang P; Slaga D; Johnston J; Bhakta S; Panowski S; Sun LL; Junttila T; Scheer JM; Ellerman DA
    MAbs; 2017 Apr; 9(3):430-437. PubMed ID: 28125314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific human IgG by design.
    Carter P
    J Immunol Methods; 2001 Feb; 248(1-2):7-15. PubMed ID: 11223065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibodies for polyclonal T-cell engagement.
    Baeuerle PA; Kufer P; Lutterbüse R
    Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.